

# Clinical Policy: Sclerotherapy and Chemical Endovenous Ablation for Varicose Veins

Reference Number: WNC.CP.130  
Last Review Date: 11/22

[Coding Implications](#)  
[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**Note:** When state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

## Description

Sclerotherapy is a minimally invasive procedure to diminish abnormally dilated and symptomatic veins.<sup>1</sup> In this procedure, liquid, foam, or glue irritants are injected into unwanted varicose veins, causing their eventual reduction.<sup>1-2</sup> This policy describes the medical necessity requirements for sclerotherapy, and endovenous ablation with chemical adhesives.

## Policy/Criteria

- I. It is the policy of WellCare of North Carolina® that sclerotherapy using liquid or foam irritants (including, but not limited to, Varithena) are medically necessary when meeting the following:
  - A. Varicose veins, **one** of the following:
    1. Perforating vein located beneath a healed or open venous ulcer, and **both** of the following:
      - a. junctional reflux  $\geq 500$  milliseconds;
      - b. diameter  $\geq 3.5$  mm;
    2. Ultrasound-documented varicosities of the greater saphenous vein, smaller saphenous vein, perforating veins, tributary veins, or accessory veins, and **both** of the following:
      - a. junctional reflux  $\geq 500$  milliseconds and/or vein diameter  $\geq 3$  mm;
      - b. complications attributed to the varicosities, including **any** of the following:
        - i. intractable ulceration;
        - ii. hemorrhage or recurrent bleeding episodes from a ruptured varicosity;
        - iii. recurrent superficial thrombophlebitis;
        - iv. severe and persistent pain and swelling, including both of the following:
          - a) duration  $\geq 6$  months;
          - b) failure of  $\geq 3$  months of conservative treatment including compression therapy, unless contraindicated (i.e. suspected or proven peripheral arterial disease, severe peripheral neuropathy, etc.);
  - B. None of the following contraindications:
    1. Previous administration of sclerotherapy agent  $< 6$  weeks prior;
    2. Allergy to sclerotherapy agent;
    3. Pregnant or within 3 months after delivery;
    4. Acute febrile illness;
    5. Local or general infection;
    6. Severe distal arterial occlusive disease (ankle-brachial index 0.4 or less);
    7. Critical limb ischemia, arterial ulcer(s), gangrene;
    8. Obliteration of deep venous system;

## CLINICAL POLICY

### SCLEROTHERAPY FOR VARICOSE VEINS

9. Recent deep venous thrombosis;
  10. Acute deep venous thrombophlebitis or acute superficial thrombophlebitis;
  11. Inability to ambulate;
  12. Tortuosity of the great saphenous vein severe enough to impede catheter placement;
  13. Klippel-Trenaunay Syndrome or other congenital venous abnormalities.
- C. If cyanoacrylate adhesive (e.g. VenaSeal™) is requested, it is for treatment of the small saphenous vein only.

**II.** It is the policy of WellCare of North Carolina® that sclerotherapy is **not medically necessary** for any of the following indications:

- A. Asymptomatic varicose veins
  1. Superficial reticular veins and/or telangiectasias;
- B. For the treatment of all other conditions than those specified above.

#### Background

Varicose veins are enlarged, twisted blood vessels often found in the lower extremities and can cause significant pain and discomfort and can negatively impact quality of life.<sup>1,6-8</sup> Varicose veins are considered a sign of chronic venous insufficiency, a condition characterized by dysfunction of the valves in veins, which can cause increased blood pressure, blood pooling, and venous reflux in affected areas.<sup>6</sup> Additionally, varicose veins can cause superficial thrombophlebitis, bleeding, and ulceration. The pathophysiology that leads to varicosities include inadequate muscle pump function, incompetent venous valves (reflux), venous thrombosis, and nonthrombotic venous obstruction.<sup>9</sup>

#### Sclerotherapy

According to clinical practice guidelines by the Society for Vascular Surgery and the American Venous Forum, sclerotherapy is a recommended treatment option for varicose veins.<sup>2</sup>

Sclerotherapy is a minimally invasive and cost effective procedure used to treat varicose veins.<sup>3,10-11</sup> To perform this procedure, chemical irritants are injected into the unwanted vein to close varicosities.<sup>1-2,9-10</sup> Destruction of venous endothelial cells and the formation of a fibrotic obstruction facilitate the venous closure due to injection of sclerosing agents.<sup>2,12</sup> Liquid and foam sclerotherapy are the two predominant modalities for the introduction of sclerosing agents;<sup>2,8</sup> Categories of sclerosing agents include osmotic, alcohol and detergent agents.<sup>2</sup>

Systematic reviews of randomized controlled trials of sclerotherapy have found that choice of sclerosing agents, dose, formulation (foam versus liquid), among other factors lack a significant effect on the efficacy of sclerotherapy for varicose veins.<sup>7,10</sup> Trials using standardized sclerosant doses and clearly defined outcomes are needed in order to obtain higher quality evidence.<sup>7</sup>

There is no consensus in the literature regarding the optimal number of sclerotherapy treatments required to reduce the symptoms associated with varicose veins. Treatment of symptomatic recurrent varicose veins should be performed after careful evaluation of the patient with duplex scanning to assess the etiology, source, type, and extent of recurrent varicose veins.<sup>2</sup>

Unnecessary retreatment of an effectively sclerosed vein should not be performed since retreatment of any single area should be delayed for 6–8 weeks to allow the treated veins to completely heal.<sup>6</sup> *Endovenous ablation with cyanoacrylate*

## CLINICAL POLICY

### SCLEROTHERAPY FOR VARICOSE VEINS

Although cyanoacrylate adhesive has been introduced as a chemical adhesive for use in endovenous ablation, future follow-up studies are needed to support the efficacy and safety in treatment of varicose veins. The notable literature currently consists of a retrospective and a prospective study without randomization.<sup>13</sup> Further long-term studies are needed to support the use of cyanoacrylate prior to integration into medical necessity guidelines.<sup>13</sup>

#### Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2021, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT® Codes	Description
<b>SUPPORT MEDICAL NECESSITY</b>	
36465	Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; single incompetent extremity truncal vein (eg, great saphenous vein, accessory saphenous vein)
36466	Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; multiple incompetent truncal veins (eg, great saphenous vein, accessory saphenous vein), same leg
36470	Injection of sclerosant; single incompetent vein (other than telangiectasia)
36471	Injection of sclerosant; multiple incompetent veins (other than telangiectasia), same leg
36482	Endovenous ablation therapy of incompetent vein, extremity, by transcatheter delivery of a chemical adhesive (eg, cyanoacrylate) remote from the access site, inclusive of all imaging guidance and monitoring, percutaneous; first vein treated
36483	Endovenous ablation therapy of incompetent vein, extremity, by transcatheter delivery of a chemical adhesive (eg, cyanoacrylate) remote from the access site, inclusive of all imaging guidance and monitoring, percutaneous; subsequent vein(s) treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure)

HCPCS® Codes	Description
No applicable codes.	

#### ICD-10-CM Diagnosis Codes that Support Coverage Criteria

ICD-10-CM Code	Description
No applicable codes.	

**CLINICAL POLICY**  
**SCLEROTHERAPY FOR VARICOSE VEINS**



Reviews, Revisions, and Approvals	Reviewed Date	Approval Date
Original approval date	03/21	06/21
Renamed policy from “Sclerotherapy for Varicose Veins” to “Sclerotherapy and Chemical Endovenous Ablation for Varicose Veins.” Clarified in Section III that cyanoacrylate is used in endovenous ablation and not sclerotherapy. Updated background accordingly. References updated.	02/22	05/22
Annual review. Added I.C, that if cyanoacrylate adhesive (VenaSeal) is requested, it is for the small saphenous vein only. Removed section III stating that cyanoacrylate adhesive is not medically necessary. Removed table of codes that do not support medical necessity and added codes 36482 and 36483 to table of codes that support medical necessity. References reviewed and updated. Description and background updated with no impact on criteria.	11/22	

**References**

1. Scovell S. Injection sclerotherapy techniques for the treatment of telangiectasias, reticular veins, and small varicose veins. UpToDate. [www.uptodate.com](http://www.uptodate.com). Published January 14, 2022. Accessed March 09, 2022
2. Kabnick LS, Scovell S. Overview of lower extremity chronic venous disease. UpToDate. [www.uptodate.com](http://www.uptodate.com). Published September 22, 2020. Accessed March 09, 2022.
3. Behraves, S, Yakes W, Gupta N., et al. Venous malformations: clinical diagnosis and treatment. *Cardiovascular Diagnosis and Therapy* 2016;6(6):557-569. doi:10.21037/cdt.2016.11.10.
4. Gloviczki P., Comerota AJ, Dalsing MC, et al; The care of patients with varicose veins and associated chronic venous diseases: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum; *J Vasc Surg* 2011;53(5 Suppl):2S-48S. doi:10.1016/j.jvs.2011.01.079
5. Almeida JI, Wakefield T, Kabnick LS, Onyeachom UN, Lal BK.. Use of the Clinical, Etiologic, Anatomic, and Pathophysiologic classification and Venous Clinical Severity Score to establish a treatment plan for chronic venous disorders. *J Vasc Surg: Venous Lymphat Disord.* 2015;3(4)456-60. doi:10.1016/j.jvsv.2015.05.007
6. Weiss MA, Hsu JT, Neuhaus I, Sadick NS, Duffy DM.. Consensus for sclerotherapy. *Dermatologic Surgery* 2014;40(12):1309-1318. doi:10.1097/DSS.0000000000000225.
7. Kaygin MA, Halici U. Evaluation of liquid or foam sclerotherapy in small varicose veins (ceap c1) with venous clinical severity score. *Rev Assoc Med Bras* (1992).. 2018;64(12):1117-1121. doi:10.1590/1806-9282.64.12.1117.
8. Koramaz İ, El Kılıç H, Gökalg F, et al. Ablation of the great saphenous vein with nontumescent n-butyl cyanoacrylate versus endovenous laser therapy. *J Vasc Surg Venous Lymphat Disord.* 2017;5(2):210-215. doi: 10.1016/j.jvsv.2016.09.007.
9. Lim CS, Davies AH. Graduated compression stockings. *CMAJ.* 2014;186(10):E391-E398. doi:10.1503/cmaj.131281

## CLINICAL POLICY

### SCLEROTHERAPY FOR VARICOSE VEINS

10. de Ávila Oliveira R, Riera R, Vasconcelos V, Baptista-Silva JC. Injection sclerotherapy for varicose veins. *Cochrane Database Syst Rev.* 2021;12(12):CD001732. Published 2021 Dec 10. doi:10.1002/14651858.CD001732.pub3
11. Worthington-Kirsch RL. Injection Sclerotherapy. *Semin Intervent Radiol.* 2005;22(3):209-17. doi: 10.1055/s-2005-921954.
12. Health Technology Assessment. Cyanoacrylate Embolization (VenaSeal Closure System) for the Treatment of Varicose Veins. Hayes. [www.hayesinc.com](http://www.hayesinc.com). Published October 31, 2019 (annual review December 09, 2021). Accessed March 08, 2022.
13. Armstrong DG, Meyr AJ. Compression therapy for the treatment of chronic venous insufficiency. *UpToDate.* [www.uptodate.com](http://www.uptodate.com). Updated July 06, 2021. Accessed March 08, 2022.

### **North Carolina Guidance**

#### *Eligibility Requirements*

- a. An eligible beneficiary shall be enrolled in either:
  1. the NC Medicaid Program (Medicaid is NC Medicaid program, unless context clearly indicates otherwise); or
  2. the NC Health Choice (NCHC is NC Health Choice program, unless context clearly indicates otherwise) Program on the date of service and shall meet the criteria in this policy.
- b. Provider(s) shall verify each Medicaid or NCHC beneficiary's eligibility each time a service is rendered.
- c. The Medicaid beneficiary may have service restrictions due to their eligibility category that would make them ineligible for this service.
- d. Following is only one of the eligibility and other requirements for participation in the NCHC Program under GS 108A-70.21(a): Children must be between the ages of 6 through 18.

#### *EPSDT Special Provision: Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age*

- a. 42 U.S.C. § 1396d(r) [1905(r) of the Social Security Act]  
Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) is a federal Medicaid requirement that requires the state Medicaid agency to cover services, products, or procedures for Medicaid beneficiary under 21 years of age if the service is medically necessary health care to correct or ameliorate a defect, physical or mental illness, or a condition [health problem] identified through a screening examination (includes any evaluation by a physician or other licensed practitioner).

This means EPSDT covers most of the medical or remedial care a child needs to improve or maintain his or her health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems.

Medically necessary services will be provided in the most economic mode, as long as the treatment made available is similarly efficacious to the service requested by the beneficiary's physician, therapist, or other licensed practitioner; the determination process does not delay

## CLINICAL POLICY

### SCLEROTHERAPY FOR VARICOSE VEINS

the delivery of the needed service; and the determination does not limit the beneficiary's right to a free choice of providers.

EPSDT does not require the state Medicaid agency to provide any service, product or procedure:

1. that is unsafe, ineffective, or experimental or investigational.
2. that is not medical in nature or not generally recognized as an accepted method of medical practice or treatment.

Service limitations on scope, amount, duration, frequency, location of service, and other specific criteria described in clinical coverage policies may be exceeded or may not apply as long as the provider's documentation shows that the requested service is medically necessary "to correct or ameliorate a defect, physical or mental illness, or a condition" [health problem]; that is, provider documentation shows how the service, product, or procedure meets all EPSDT criteria, including to correct or improve or maintain the beneficiary's health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems.

#### **EPSDT and Prior Approval Requirements**

1. If the service, product, or procedure requires prior approval, the fact that the beneficiary is under 21 years of age does NOT eliminate the requirement for prior approval.
2. **IMPORTANT ADDITIONAL INFORMATION** about EPSDT and prior approval is found in the *NCTracks Provider Claims and Billing Assistance Guide*, and on the EPSDT provider page. The Web addresses are specified below:

*NCTracks Provider Claims and Billing Assistance Guide:*

<https://www.nctracks.nc.gov/content/public/providers/provider-manuals.html>

*EPSDT provider page:* <https://medicaid.ncdhhs.gov/>

EPSDT does not apply to NCHC beneficiaries.

#### *Provider(s) Eligible to Bill for the Procedure, Product, or Service*

To be eligible to bill for the procedure, product, or service related to this policy, the provider(s) shall:

- a. meet Medicaid or NCHC qualifications for participation;
- b. have a current and signed Department of Health and Human Services (DHHS) Provider Administrative Participation Agreement; and
- c. bill only for procedures, products, and services that are within the scope of their clinical practice, as defined by the appropriate licensing entity.

#### *Compliance*

Provider(s) shall comply with the following in effect at the time the service is rendered:

- a. All applicable agreements, federal, state and local laws and regulations including the Health Insurance Portability and Accountability Act (HIPAA) and record retention requirements; and
- b. All NC Medicaid's clinical (medical) coverage policies, guidelines, policies, provider manuals, implementation updates, and bulletins published by the Centers for Medicare and Medicaid Services (CMS), DHHS, DHHS division(s) or fiscal contractor(s).

## CLINICAL POLICY

### SCLEROTHERAPY FOR VARICOSE VEINS

#### *Claims-Related Information*

Provider(s) shall comply with the, NC Tracks Provider Claims and Billing Assistance Guide, Medicaid bulletins, fee schedules, NC Medicaid's clinical coverage policies and any other relevant documents for specific coverage and reimbursement for Medicaid and NCHC:

- a. Claim Type - as applicable to the service provided:
  - Professional (CMS-1500/837P transaction)
  - Institutional (UB-04/837I transaction)Unless directed otherwise, Institutional Claims must be billed according to the National Uniform Billing Guidelines. All claims must comply with National Coding Guidelines.
- b. International Classification of Diseases and Related Health Problems, Tenth Revisions, Clinical Modification (ICD-10-CM) and Procedural Coding System (PCS) - Provider(s) shall report the ICD-10-CM and Procedural Coding System (PCS) to the highest level of specificity that supports medical necessity. Provider(s) shall use the current ICD-10 edition and any subsequent editions in effect at the time of service. Provider(s) shall refer to the applicable edition for code description, as it is no longer documented in the policy.
- c. Code(s) - Provider(s) shall report the most specific billing code that accurately and completely describes the procedure, product or service provided. Provider(s) shall use the Current Procedural Terminology (CPT), Health Care Procedure Coding System (HCPCS), and UB-04 Data Specifications Manual (for a complete listing of valid revenue codes) and any subsequent editions in effect at the time of service. Provider(s) shall refer to the applicable edition for the code description, as it is no longer documented in the policy. If no such specific CPT or HCPCS code exists, then the provider(s) shall report the procedure, product or service using the appropriate unlisted procedure or service code.

#### *Unlisted Procedure or Service*

CPT: The provider(s) shall refer to and comply with the Instructions for Use of the CPT Codebook, Unlisted Procedure or Service, and Special Report as documented in the current CPT in effect at the time of service.

HCPCS: The provider(s) shall refer to and comply with the Instructions For Use of HCPCS National Level II codes, Unlisted Procedure or Service and Special Report as documented in the current HCPCS edition in effect at the time of service

- d. Modifiers - Providers shall follow applicable modifier guidelines.
- e. Billing Units - Provider(s) shall report the appropriate code(s) used which determines the billing unit(s).
- f. Co-payments -
  - For Medicaid refer to Medicaid State Plan:  
<https://medicaid.ncdhhs.gov/get-involved/nc-health-choice-state-plan>
  - For NCHC refer to NCHC State Plan:  
<https://medicaid.ncdhhs.gov/get-involved/nc-health-choice-state-plan>
- g. Reimbursement - Provider(s) shall bill their usual and customary charges. For a schedule of rates, refer to: <https://medicaid.ncdhhs.gov/>.

#### **Important Reminder**

## CLINICAL POLICY

### SCLEROTHERAPY FOR VARICOSE VEINS

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.



**CLINICAL POLICY**  
**SCLEROTHERAPY FOR VARICOSE VEINS**

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.

DRAFT